
- Roche’s Tecentriq scores a first-in-class double win in new liver cancer patients FiercePharma
- Roche pushes late-comer Tecentriq as new liver cancer option Reuters
- Roche immunotherapy cocktail boosts survival in liver cancer Nasdaq
- Roche eyes filings for Tecentriq/Avastin combo in liver cancer pmlive.com
- View full coverage on Google News
